Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
BIVI

BIVI - BioVie Inc. Stock Price, Fair Value and News

$1.24+0.03 (+2.48%)
Market Closed

63/100

BIVI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

63/100

BIVI

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$1.48

Target 3M

$1.28

Target 6M

$1.35

BIVI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIVI Price Action

Last 7 days

3.3%

Last 30 days

0.8%

Last 90 days

-29.9%

Trailing 12 Months

-93.1%

BIVI RSI Chart

BIVI Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

BIVI Valuation

Market Cap

9.3M

Price/Earnings (Trailing)

-0.51

Price/Sales (Trailing)

10.46

Price/Free Cashflow

-0.51

BIVI Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$1.48

Target 3M

$1.28

Target 6M

$1.35

BIVI Fundamentals

BIVI Revenue

Revenue (TTM)

893.6K

Rev. Growth (Yr)

-10.97%

Rev. Growth (Qtr)

-21.34%

BIVI Earnings

Earnings (TTM)

-18.5M

Earnings Growth (Yr)

-22.53%

Earnings Growth (Qtr)

-45.81%

BIVI Profitability

Return on Equity

-74.14%

Return on Assets

-68.89%

Free Cashflow Yield

-197.54%

BIVI Investor Care

Shares Dilution (1Y)

324.37%

Diluted EPS (TTM)

-11.44

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
202500893.6K0
2024001.0M1.2M
2023152.8K239.0K659.7K794.4K
202240.2K44.1K78.0K149.6K
2021022.0K28.8K35.6K
20200000
20190000
20180000
20170000
20160000
20150000
Get all data in R, Python etc through our Historical Stock Data APIs

About BioVie Inc.

BIVI
BioVie Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of drugs for the treatment of chronic debilitating conditions in the United States. Its products pipeline includes BIV201, which completed Phase IIa clinical trial for the treatment of ascites caused due to chronic liver cirrhosis; and NE3107, a potentially selective inhibitor of inflammatory extracellular single-regulated kinase, which is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease, as well as Phase 2 clinical trial for the treatment of Parkinson's disease. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada.
 CEO
 WEBSITEhttps://bioviepharma.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES18

BioVie Inc. Frequently Asked Questions

BIVI is the stock ticker symbol of BioVie Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of BioVie Inc. is 9.35 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check BIVI's fair value in chart for subscribers.

The fair value guage provides a quick view whether BIVI is over valued or under valued. Whether BioVie Inc. is cheap or expensive depends on the assumptions which impact BioVie Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for BIVI.

As of Wed Jan 28 2026, BIVI's PE ratio (Price to Earnings) is -0.51 and Price to Sales (PS) ratio is 10.46. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. BIVI PE ratio will change depending on the future growth rate expectations of investors.